Merck Group courts US, China investors to accelerate immune-oncology development

Armed with several Phase II and Phase III immunology and oncology assets, Merck KGaA is courting US and Chinese Investors to fund these projects, for an amount of USD 100–200 million, the head of external innovation Ravi Kiron says. He outlines to Brian Yang that Merck Group is also looking at emerging technologies including gene-editing and artificial intelligence (AI) to help speed up new drug development. The interview was conducted at China Showcase ahead of Biotech Showcase and JP Morgan Global Healthcare Conference.